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undergoing surgery with spinal block: the Swiss Beta Blocker in
Spinal Anesthesia (BBSA) study: a double-blinded,
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Abstract
BACKGROUND: Neuraxial blockade is used as primary anesthetic technique in one third of surgical
procedures. The authors tested whether bisoprolol would protect patients at risk for cardiovascular
complications undergoing surgery with spinal block. METHODS: The authors performed a
double-blinded, placebo-controlled, multicenter trial to compare the effect of bisoprolol with that of
placebo on 1-yr composite outcome including cardiovascular mortality, nonfatal myocardial infarction,
unstable angina, congestive heart failure, and cerebrovascular insult. Bisoprolol was given orally before
and after surgery for a maximum of 10 days. Adrenergic receptor polymorphisms and safety outcome
measures of bisoprolol therapy were also determined. RESULTS: A total of 224 patients were enrolled.
Spinal block could not be established in 5 patients. One hundred ten patients were assigned to the
bisoprolol group, and 109 patients were assigned to the placebo group. The mean duration of treatment
was 4.9 days in the bisoprolol group and 5.1 days in the placebo group. Bisoprolol therapy reduced
mean heart rate by 10 beats/min. The primary outcome was identical between treatment groups and
occurred in 25 patients (22.7%) in the bisoprolol group and 24 patients (22.0%) in the placebo group
during the 1-yr follow-up (hazard ratio, 0.97; 95% confidence interval, 0.55-1.69; P = 0.90). However,
carriers of at least one Gly allele of the beta1-adrenergic receptor polymorphism Arg389Gly showed a
higher number of adverse events than Arg homozygous (32.4% vs. 18.7%; hazard ratio, 1.87; 95%
confidence interval, 1.04-3.35; P = 0.04). CONCLUSIONS: Perioperative bisoprolol therapy did not
affect cardiovascular outcome in these elderly at-risk patients undergoing surgery with spinal block.
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Adrenergic Receptor Genotype but Not Perioperative
Bisoprolol Therapy May Determine Cardiovascular Outcome
in At-risk Patients Undergoing Surgery with Spinal Block
The Swiss Beta Blocker in Spinal Anesthesia (BBSA) Study: A Double-blinded,
Placebo-controlled, Multicenter Trial with 1-Year Follow-up
Michael Zaugg, M.D.,* Lukas Bestmann, Ph.D.,† Johannes Wacker, M.D.,‡ Eliana Lucchinetti, Ph.D.,§ Anita Boltres, M.D.,
Christian Schulz, M.D., Martin Hersberger, Ph.D.,# Gabriela Ka¨lin, B.Sc.,** Lukas Furrer, M.D.,†† Christoph Hofer, M.D.,‡‡
Stephan Blumenthal, M.D.,§§ Annabelle Mu¨ller, Ph.D., Andreas Zollinger, M.D.,## Donat R. Spahn, M.D.,*** Alain Borgeat, M.D.†††
Background: Neuraxial blockade is used as primary anesthetic
technique in one third of surgical procedures. The authors tested
whether bisoprolol would protect patients at risk for cardiovascular
complications undergoing surgery with spinal block.
Methods: The authors performed a double-blinded, placebo-
controlled, multicenter trial to compare the effect of bisoprolol
with that of placebo on 1-yr composite outcome including cardio-
vascular mortality, nonfatal myocardial infarction, unstable an-
gina, congestive heart failure, and cerebrovascular insult. Bisopro-
lol was given orally before and after surgery for a maximum of 10
days. Adrenergic receptor polymorphisms and safety outcome
measures of bisoprolol therapy were also determined.
Results: A total of 224 patients were enrolled. Spinal block could
not be established in 5 patients. One hundred ten patients were
assigned to the bisoprolol group, and 109 patients were assigned
to the placebo group. Themean duration of treatmentwas 4.9 days
in the bisoprolol group and 5.1 days in the placebo group. Biso-
prolol therapy reduced mean heart rate by 10 beats/min. The
primary outcome was identical between treatment groups and
occurred in 25 patients (22.7%) in the bisoprolol group and 24
patients (22.0%) in the placebo group during the 1-yr follow-up
(hazard ratio, 0.97; 95% confidence interval, 0.55–1.69; P  0.90).
However, carriers of at least one Gly allele of the 1-adrenergic
receptor polymorphism Arg389Gly showed a higher number of
adverse events than Arg homozygous (32.4% vs. 18.7%; hazard
ratio, 1.87; 95% confidence interval, 1.04–3.35; P  0.04).
Conclusions: Perioperative bisoprolol therapy did not affect
cardiovascular outcome in these elderly at-risk patients under-
going surgery with spinal block.
CARDIOVASCULAR morbidity and mortality after major
noncardiac surgery is high in patients with or at risk of
coronary artery disease. Approximately 1 in 10 patients
must be expected to have cardiovascular complica-
tions.1‡‡‡ The costs and disease burden arising from
these complications form the rationale for preoperative
risk assessment and preventive medical therapies.2,3
Based on two randomized trials4,5 and smaller clinical
trials6–8 reporting short- and long-term cardiovascular
benefits with perioperative  blockade, the American
Heart Association and the American College of Cardiol-
ogists recommended the use of  blockers among high-
risk patients undergoing noncardiac surgery.2,3 How-
ever, three recent placebo-controlled trials9–11 could not
confirm these initial promising results, calling into ques-
tion whether the previous findings can be generalized to
the majority of surgical patients.
Neuraxial blockade is used as primary anesthetic tech-
nique in one third of surgical procedures, but its inter-
action with the putative benefits of  blockade remains
elusive. Neuraxial blockade per se has several physio-
logic effects that could potentially improve cardiovascu-
lar outcome.12 Direct administration of drugs to the
spinal cord completely blocks pain fibers, thus prevent-
ing activation of the sympathetic nerve system, a key
element in the pathogenesis of perioperative myocardial
ischemia.13 In fact, a large meta-analysis reported a re-
duction in mortality and myocardial infarction (of ap-
proximately 30%) in patients undergoing surgery with
this technique compared with general anesthesia.14 Con-
versely, the combination of two antiadrenergic strategies
may harbor the threat of severe bradycardia and hypo-
tension precipitating myocardial injury and cardiac ar-
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rest, which could abrogate the benefits of  blockade.15
To date, no study has systematically investigated the
short- and long-term cardiovascular effects of acute 
blockade in patients undergoing surgery with neuraxial
blockade.
Genetic polymorphisms of the -adrenergic receptor
genes alter receptor physiology and act as important
disease modifiers.16–19 Sequence variants were recently
reported to influence the response to -blocker treat-
ment and to affect outcome.20 Therefore, “average” ben-
eficial and detrimental effects observed in clinical trials
may result from subgroups of patients with a particular
genetic background. To address this important con-
founding variable, four physiologically relevant nonsyn-
onymous coding variants of the -adrenergic receptor
were determined in the study population.
We here report the results of a double-blinded, place-
bo-controlled clinical trial designed to test the hypothe-
sis that the perioperative administration of bisoprolol
reduces the incidence of cardiovascular complications
defined as cardiovascular death, nonfatal myocardial in-
farction, congestive heart failure, and cerebral stroke in
patients with or at risk for coronary artery disease un-
dergoing surgery with spinal nerve block.
Materials and Methods
The Swiss Beta Blocker in Spinal Anesthesia (BBSA)
study is a placebo-controlled, randomized trial with 1-yr
follow-up, four participating centers (University Hospital
Zurich, Orthopedic University Clinic Balgrist Zurich, Tri-
emli Hospital Zurich, and University Hospital Lausanne),
and blinding of all involved personnel. Blinding was
maintained through selection, treatment, follow-up, data
management, and analysis. The local ethics committees
of the four hospital centers approved this study, and
written informed consent was obtained from all patients.
Study Population and Treatment
Between January 2003 and January 2005, 224 patients
scheduled to undergo surgery with spinal block were
enrolled in this study. The randomization process used
block randomization in a 1:1 ratio stratified by center.
Inclusion criteria were (1) presence of coronary artery
disease indicated by previous myocardial infarction, typ-
ical angina, atypical angina with a positive stress test, or
history of coronary surgery and/or coronary interven-
tion; (2) presence of at least two risk factors for coronary
artery disease, including hypertension, diabetes, hyper-
cholesterolemia (total serum cholesterol concentration
 240 mg/dl or low-density lipoprotein cholesterol
 160 mg/dl and high-density lipoprotein cholesterol
 40 mg/dl), age older than 65 yr, and active smoking;
and (3) duration of in-hospital stay of at least 24 h.
Exclusion criteria were (1) chronic  blockade, (2) man-
ifest congestive heart failure, (3) high-degree heart
block, (4) active asthma necessitating daily medical treat-
ment, and (5) left ventricular bundle branch block.
All patients received bisoprolol or placebo orally at
least 3 h before spinal block and surgery. The study drug
was titrated to heart rate and blood pressure. If systolic
blood pressure was greater than 120 mmHg and heart
rate was greater than 65 beats/min, 10 mg of study drug
was given. If systolic blood pressure was less than 100
mmHg or heart rate was less than 50 beats/min, the
study drug was withheld. In all other cases, 5 mg of
study drug was given. In case of impossible oral admin-
istration of the study drug, intravenous metoprolol or
matching placebo could be given, but was only neces-
sary for a single application in one patient. All patients
received 500 ml Ringer’s solution before induction of
spinal block. Spinal block was achieved in lateral or
supine position at the L3–L4 or L4–L5 segment with
12–15 mg hyperbaric bupivacaine, 0.5%, and supple-
mented with clonidine (1–2 g/kg) as per the attending
anesthesiologist. Episodes of hypotension (systolic blood
pressure  100 mmHg) and bradycardia ( 50 beats/
min) were treated with changing positioning, additional
fluid administration, ephedrine, and atropine, respec-
tively. Study drug was again administered within the first
6 h after the end of surgery. The treatment was contin-
ued until hospital discharge or for a maximum of 10
days. Administration of the study drug was always ti-
trated to heart rate and blood pressure.
Outcome Measures and Follow-up
The primary outcome measure was time to the com-
posite outcome of cardiovascular mortality, nonfatal
myocardial infarction, unstable angina, congestive heart
failure, and cerebrovascular insult. In the presence of
more than one outcome, the time of the first event was
recorded. Death was considered a result of cardiovascu-
lar cause if the patient died of myocardial infarction,
arrhythmia, congestive heart failure, or cerebral stroke.
The diagnosis of a nonfatal myocardial infarction re-
quired a new Q wave, persistent ST–T-segment changes
as defined by Minnesota Codes,21 and/or association
with elevated creatine kinase MB isoenzyme activity
(above double the upper normal concentration) and/or
troponins, or documentation of myocardial infarction in
the medical chart. Unstable angina was diagnosed in
patients with typical pain but no rise in cardiac enzymes
together with an ad hoc medical intervention for unsta-
ble angina, or ST-segment depression, or T-wave inver-
sion. The following events were used for the diagnosis of
congestive heart failure: (1) a change in cardiovascular
medication including start of medication, increasing
dose of existing medication, or new class of medication
for heart failure together with (2) at least one of the
following two criteria: (a) clinical signs of pulmonary
congestion or (b) abnormal results on chest x-ray. The
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diagnosis of a cerebrovascular insult required the pres-
ence of clinical symptoms and a positive computer-as-
sisted tomography scan. Short-term follow-up included
perioperative Holter electrocardiography, collection of
blood samples (before surgery, immediately after sur-
gery, at 24, 48, and 72 h, and at discharge), and pulmo-
nary function measurements before and after study drug
administration. All patients had prospectively scheduled
medical consultations at 6 and 12 months after the op-
eration, independent of their usual clinical care, with
12-lead electrocardiogram and collection of blood sam-
ples. In addition, each patient’s general physician was
asked to prospectively record information on cardiovas-
cular events and medication. Serious adverse events lead-
ing to withdrawal of the study drug were also recorded.
Secondary outcomes were related to safety of perioper-
ative bisoprolol therapy in patients undergoing surgery
with spinal block and included perioperative occurrence
of bradycardia ( 50 beats/min), hypotension (systolic
blood pressure  100 mmHg), and pulmonary function.
From all blood samples, cardiac enzymes and N-terminal
pro brain natriuretic peptide were determined. Pregnan-
cy-associated plasma protein A and cystatin C were mea-
sured before surgery, 24 h (pregnancy-associated plasma
protein A) or 72 h (cystatin C) after surgery, and 6 and 12
months later.
Cardiovascular Biomarkers
Blood samples were stored at 80°C until analysis.
The following parameters were determined using the
Roche Modular Analytics P or the Roche Modular Ana-
lytics E170 (Roche Diagnostics, Mannheim, Germany) as
previously described22: N-terminal brain natriuretic pep-
tide (electrochemiluminescence immunoassay)—sensi-
tivity  5 ng/l; intraassay and interassay coefficients of
variance  3%; normal value (97.5th percentile) for men
aged  50 yr,  334 ng/l; normal value for women aged
 50 yr,  227 ng/l; cardiac troponin T (electrochemi-
luminescence immunoassay)—sensitivity  0.01 g/l;
intraassay and interassay coefficients of variance 2.5%;
normal value  0.01 g/l; total creatine kinase (enzy-
matic reaction with formation of reduced nicotinamide
adenine dinucleotide phosphate)—sensitivity 2 U/l; in-
traassay and interassay coefficients of variance  2%;
normal value for men  170 U/l; normal value for
women  145 U/l; creatine kinase MB activity (immu-
nologic ultraviolet assay)—sensitivity 5 U/l; intraassay
and interassay coefficients of variance  2%; normal
value  24 U/l; pregnancy-associated plasma protein A
assays, purchased from Brahms, Henningsdorf, Germany
(immunometric assay based on time resolved amplifica-
tion cryptate emission)—sensitivity 0.004 U/l; intraassay
and interassay coefficients of variance  2%; normal
range (healthy male)  0.01 U/l; and cystatin C assays,
purchased from Dako A/S, Goldstrup, Denmark (particle-
enhanced turbidimetric assay)—sensitivity  0.2 mg/dl;
intraassay and interassay coefficients of variance 3.5%;
normal range 0.74–1.5 mg/l.
Holter Electrocardiography
Analysis of Holter electrocardiography data was per-
formed as previously described.23 Briefly, three-channel
digital Holter electrocardiography monitoring was be-
gun at least 2 h before surgery and continued for 24 h
postoperatively (8500 series; GE Marquette Medical Sys-
tems, Milwaukee, WI). Seven bipolar leads were simul-
taneously recorded using silver–silver chloride elec-
trodes. The effect of patient positional variation was
measured in supine and upright positions. Holter elec-
trocardiography data were analyzed for cardiac rhythm
and ST-segment changes (Marquette Holter analysis sys-
tem software version 8500; GE Marquette Medical Sys-
tems) indicative of ischemia after exclusion of abnormal
QRS complexes. ST-segment changes were trended in
three leads for the duration of the recording. Baseline
ST-segment levels were defined as the average ST-seg-
ment during stable periods (at least 10 min) preceding
each ischemic period. Electrocardiographic ischemic pe-
riods were defined as reversible ST-segment changes
lasting at least 1 min and involving either a shift from
baseline of  0.1 mV of ST depression or a shift from
baseline of  0.2 mV of ST–T elevation at the J point.
ST-segment depression was measured 60 ms after the J
point, unless that point fell within the T wave, in which
case it was shortened to the J point plus 40 ms. Holter
analysis was corrected for positional variation by taking
the maximum shift noted by positional changes. The
following parameters were measured as indicators of the
severity of each ischemic episode: total episodes per
patient with ischemia, maximal ST depression, duration
of longest ischemic episode, total area under the curve
(defined as the integral of ST depression in mV  dura-
tion), and maximal area under the curve. Perioperative
time was divided into three separate episodes (preoper-
ative period, intraoperative period, postoperative pe-
riod). Holter electrocardiography recordings were also
analyzed for the occurrence of dysrhythmias using the
aforementioned software. Ventricular and supraventric-
ular ectopic beats were identified and counted. The
number of runs and the percentage of recorded time
with atrial fibrillation were calculated separately for each
period.
Pulmonary Function
Vital capacity, forced vital capacity, forced expiratory
volume in 1 s, mid expiratory flow, and peak expiratory
flow were determined in an upright position of the
upper body at the preoperative assessment (baseline
without study drug) and 24 h after surgery using a
portable spirometer (MicroLab ML3500; Labhardt AG,
Basel, Switzerland). The physiologic parameters were
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compared between the bisoprolol and the placebo
group and related to the ADRB2 polymorphisms.
Genotyping
One hundred eighty-nine patients consented to ge-
netic analysis. Two polymorphisms in the 1-adrenergic
receptor (ADRB1), namely ADRB1 Ser49Gly (refSNP
ID§§§: rs1801252) and ADRB1 Arg389Gly (refSNP ID:
rs1801253), and two polymorphisms in the 2-adrener-
gic receptor (ADRB2), namely ADRB2 Gly16Arg (refSNP
ID: rs1042713) and ADRB2 Gln27Glu (refSNP ID:
rs1042714), were determined. Blood was obtained in
5-ml EDTA tubes. DNA was isolated either by a standard
rapid lysis technique using the Qiagen QIAamp Blood kit
(Qiagen, Hilden, Germany) or on a MagNA Pure LC
system (Roche Diagnostics, Rotkreuz, Switzerland) and
genotyped on a LightCycler instrument (Roche Molecu-
lar Biochemicals, Rotkreuz, Switzerland). The LightCy-
cler is a combined microliter volume thermal cycler and
fluorometer suitable for fast real-time fluorescence poly-
merase chain reaction. It is also designed for mutation
detection by melting point analysis with fluorescent hy-
bridization probes using the fluorescence energy trans-
fer principle. LightCycler polymerase chain reaction pro-
tocols for the detection of the polymorphisms were
developed. Usually, the test setup for the detection of
the single nucleotide polymorphism is based on the
principle of mutation detection by melting curve analy-
sis with fluorescence energy transfer hybridization
probes, using 6-carboxyfluorescein as donor molecule
and LCRed 640 or LCRed 705 as acceptor molecules. The
probes for the detection of the single nucleotide poly-
morphisms on the ADRB1 and ADRB2 segments were
covered with only one dual-labeled probe, either fitting
with the wild type or fitting with the mutation sequence.
Hence, the probes were designed as beacons; the re-
porter dye was 6-carboxyfluorescein (detection channel
530 nm) for the wild type or Yakima Yellow (detection
channel 560 nm) for the mutated alleles and the quench-
ing molecule dabcyl. The modifications for the LightCy-
cler setup (originally designed for the TaqMan instru-
ment) were done as previously described.24 The
presence of a wild type evoked a clear amplification
signal at the detecting wavelength of the wild-type
probes, the homozygous mutated at the wavelength at
which the mutated probes were labeled, and the het-
erozygous gave at both wavelengths a clear signal. For
the analysis of the selected polymorphisms in the
ADRB2, a single primer pair was used because the poly-
morphisms are in close proximity on the segment. Prim-
ers and probes were as previously published.24 Addi-
tional technical information regarding the genotyping
protocols is available on the ANESTHESIOLOGY Web site at
http://www.anesthesiology.org (table S1). In separate
experiments, DNA samples from 12 randomly selected
patients were tested with these LightCycler protocols
and afterward subjected to sequencing for the ADRB1
and ADRB2 on the ABI 310 prism sequencer
(PerkinElmer, Schwerzenbach, Switzerland) and used as
controls.
Statistical Analysis
Mangano et al.4 reported an event-free survival of 92%
in the atenolol group and of 78% in the placebo group at
1 yr of follow-up. Based on these data, we estimated a
minimum sample size of 101 patients in each group with
a two-sided   0.05 and a power of 80% (log rank test
of event-free survival in two groups followed for a fixed
time; nQuery Advisor, Statistical Solutions, Cork, Ire-
land) was required. Kaplan-Meier event-free survival
curves were compared by log rank test. For biochemical
and physiologic parameters, repeated-measures analysis
of variance was used to evaluate differences over time
between groups. All other data were analyzed using an
unpaired t test for parametric data, or Mann–Whitney
tests for nonparametric data. Categorical variables were
summarized by proportions and compared using the
Fisher exact test or the chi-square test, if appropriate.
Cox proportional hazards regression was used to analyze
the effect of several risk factors (predictor variables) on
the occurrence of an event (coded “Y” if present and “N”
if absent). A screening of all putative predictor variables
was conducted using chi-square tests (contingency ta-
bles) in the case of nominal/categorical variables and
using unpaired t tests in the case of continuous variables.
All P values were recorded. In a first step, all variables
with P  0.20 entered a Cox proportional hazards re-
gression, and the model coefficients were computed.
Subsequently, all nonsignificant variables were removed
in a stepwise manner. Odd ratios and confidence inter-
vals (CIs) were computed using univariate Cox propor-
tional hazards regression models. The interaction be-
tween bradycardia (or hypotension) and clinical
predictors or genotype was tested using multivariate
logistic regression. P  0.05 was considered significant.
Data are given as mean  SD or median and quartiles, as
appropriate. Analyses were performed using StatView
Version 5 (SAS Institute, Chicago, IL).
Results
Two-hundred twenty-four patients were randomly as-
signed to bisoprolol and placebo. All patients were fol-
lowed up for 1 yr. In 5 patients (2 bisoprolol, 3 placebo),
the spinal block could not be successfully established.
These patients underwent surgery in general anesthesia
and thus were excluded from the final analysis. From the
remaining 219 patients, 110 were assigned to the bisopro-
lol group and 109 patients to the placebo group. Patient§§§ http://www.ncbi.nlm.nih.gov/SNP/index.html. Accessed January 2007.
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and perioperative characteristics were similar between
groups (table 1). Recruitment of patients as per Mangano’s
criteria resulted in approximately 75% of patients having at
least one risk factor as defined by the Dutch Echocardio-
graphic Cardiac Risk Evaluation Applying Stress Echocardi-
ography (DECREASE) Study Group25 or in approximately
50% of patients having one risk factor as defined by Lee et
al. 26 Framingham Risk assessment27 to estimate 10-yr risk
for myocardial infarction and coronary death yielded a risk
greater than 20% in 63% of the study patients (fig. S1,
available on the ANESTHESIOLOGY Web site at http://www.
anesthesiology.org). The majority of patients were under-
going orthopedic (67%) or urologic (25%) surgery. Eight
patients in the bisoprolol group and 9 patients in the
Table 1. Characteristics of Patients
Bisoprolol (n  110) Placebo (n  109)
Demographics
Age, mean (SD), yr 69 (11) 71 (10)
Number of women (%) 48 (44) 51 (47)
BMI, mean (SD), kg/m2 28 (5) 28 (5)
Heart rate, mean (SD), beats/min 75 (11) 75 (12)
Systolic blood pressure, mean (SD), mmHg 146 (22) 144 (18)
Diastolic blood pressure, mean (SD), mmHg 81 (10) 79 (10)
Cardiovascular disease
Heart failure (%) 5 (4.5) 6 (5.5)
Angina pectoris (%) 8 (7.3) 5 (4.6)
History of hypertension (%) 96 (87.3) 91 (83.5)
Hypercholesterolemia (%) 47 (42.7) 43 (39.4)
Previous myocardial infarction (%) 9 (8.2) 8 (7.3)
Pathologic Q waves on ECG (%) 3 (2.7) 7 (6.4)
Previous PTCA (%) 4 (3.6) 3 (2.8)
Previous CABG (%) 4 (3.6) 6 (5.5)
Previous stroke (%) 11 (10.0) 10 (9.2)
Limb arteriopathy
Number of patients (%) 12 (10.9) 11 (10.1)
Diabetes mellitus
Non–insulin dependent (%) 23 (20.9) 14 (12.8)
Insulin dependent (%) 7 (6.4) 7 (6.4)
Smoking
Current smoker (%) 26 (23.6) 32 (29.4)
Former smoker (%) 60 (54.5) 64 (58.7)
COPD
Number of patients (%) 16 (14.5) 17 (15.6)
Impaired renal function
Number of patients (%) 10 (9.1) 18 (16.5)
Risk factors (DECREASE)*
Number of patients (%) with score 0 28 (25.5) 25 (22.9)
Number of patients (%) with score 1 or 2 76 (69) 74 (67.9)
Number of patients (%) with score  3 6 (5.5) 10 (9.2)
Cumulative Cardiac Risk Index (Lee)†
Number of patients (%) with score 0 55 (50.0) 57 (52.3)
Number of patients (%) with score 1 or 2 51 (46.4) 49 (45.0)
Number of patients (%) with score  3 4 (3.6) 3 (2.8)
Type of surgery
Orthopedic surgery (%) 75 (68.2) 72 (66.1)
Urologic surgery (%) 26 (23.6) 29 (26.6)
Abdominal surgery (%) 4 (3.6) 2 (1.8)
Gynecologic surgery (%) 1 (0.9) 0 (0.0)
Plastic surgery (%) 1 (0.9) 4 (3.7)
Arterial vascular surgery (%) 1 (0.9) 0 (0.0)
Venous vascular surgery (%) 2 (1.8) 2 (1.8)
Duration of surgery
Mean (range), min 97 (7–240) 93 (9–253)
Duration of anesthesia
Mean (range), min 136 (41–290) 131 (28–253)
No significant differences were found between groups.
* As defined by the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) Study Group. Cardiac risk factors were
age 70 yr or older, previous myocardial infarction, congestive heart failure, cerebrovascular event, diabetes mellitus, and impaired renal function (creatinine 
170 M). † Revised Cardiac Risk Index score: ischemic heart disease, cerebrovascular disease, impaired renal function, and diabetes mellitus.
BMI  body mass index; CABG  coronary artery bypass grafting; COPD  chronic obstructive pulmonary disease; ECG  electrocardiogram; PTCA 
percutaneous transluminal coronary angioplasty.
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placebo group had received  blockers during their fol-
low-up (table 2).
Primary Outcome
Four patients (2 bisoprolol patients with fatal cerebral
stroke and fatal myocardial infarction, 2 placebo patients
with cardiac death and death due to prostate cancer)
died during the 1-yr follow-up. Twenty-five patients in
the bisoprolol group (22.7%) and 24 in the placebo
group (22.0%) had a positive primary outcome (table 3).
Figure 1 shows the Kaplan-Meier estimates of the pri-
mary outcome measure in the two groups (log rank test,
P 0.90). Primary outcome was equally distributed over
the follow-up period, and occurred in 2 bisoprolol-
treated patients during the hospital stay or within 30
days postoperatively. Table 4 shows the predictors of
the primary outcome in univariate Cox regression mod-
els. No significant effect of bisoprolol compared with
placebo was observed (hazard ratio, 0.97; CI, 0.55–1.69;
P  0.90). Lee score, occurrence of perioperative hypo-
tension or bradycardia, or presence of statin therapy did
not provide prognostic information.
One hundred eighty-nine patients were genotyped
(86.3%). Genotyping success rate was 100% for the adren-
ergic receptor polymorphisms rs1801252, rs1042713, and
rs1042714. For the ADRB1 Arg389Gly (rs1801253), geno-
type determination was successful in 92 bisoprolol- and 94
placebo-treated patients, respectively (186 of 189 patients,
Table 2. Medical Therapy at the Start of the Trial and during the 1-Year Follow-up
Cardiovascular Medication
Ca2
Antagonists Diuretics ACEIs
AT II Receptor
Blockers Nitrates Statins
Acetylsalicylic
Acid  Blockers
B P B P B P B P B P B P B P B P
Preoperative 20 (18) 19 (17) 35 (32) 45 (41) 34 (31) 34 (31) 19 (17) 19 (17) 6 (5) 2 (2) 26 (24) 23 (21) 31 (28) 26 (24) 0 (0) 0 (0)
Discharge 20 (18) 19 (17) 35 (32) 45 (41) 34 (31) 34 (31) 19 (17) 19 (17) 6 (5) 2 (2) 25 (23) 23 (21) 35 (32) 25 (23) 2 (2) 1 (1)
6 months 18 (17) 18 (17) 39 (36) 44 (40) 36 (33) 31 (28) 20 (18) 19 (17) 8 (7) 4 (4) 25 (23) 26 (24) 38 (35) 27 (25) 6 (6) 5 (5)
12 months 21 (19) 17 (16) 39 (36) 45 (42) 35 (32) 34 (32) 20 (19) 19 (18) 8 (7) 3 (3) 27 (25) 29 (27) 38 (35) 30 (28) 8 (7) 9 (8)
Diabetes Medication Other
Insulin Sulfonylureas Other Antidiabetics COX-2 Inhibitors NSAIDs
B P B P B P B P B P
Preoperative 6 (5) 7 (6) 7 (6) 5 (5) 24 (22) 10 (9) 6 (5) 6 (6) 8 (7) 6 (6)
Discharge 6 (5) 7 (6) 7 (6) 5 (5) 17 (15) 6 (6) 12 (11) 11 (10) 7 (6) 6 (6)
6 months 6 (6) 7 (6) 8 (7) 5 (5) 19 (17) 9 (8) 7 (6) 10 (9) 9 (8) 5 (5)
12 months 6 (6) 7 (7) 8 (7) 6 (6) 20 (19) 11 (10) 6 (6) 10 (9) 9 (8) 5 (5)
Data are number of patients (%). The use of cardiovascular medication was similar in the two groups.
6 months  medication at 6 months postoperatively; 12 months  medication at 12 months postoperatively; ACEI  angiotensin-converting enzyme inhibitor;
AT II  angiotensin II; B  bisoprolol; COX-2  cyclooxygenase-2; Discharge  medication at discharge; NSAID  nonsteroidal antiinflammatory drug; P 
placebo; Preoperative  medication at hospital admission.
Table 3. Primary Outcomes
Bisoprolol
(n  110)
Placebo
(n  109)
Cardiovascular death 2 1
Myocardial infarction 2 1
Stroke 2 2
Unstable angina 3 4
Congestive heart failure 16 16
All 25 24
Fig. 1. Kaplan-Meier plot for adverse events during 1 yr of
follow-up after perioperative bisoprolol and placebo therapy in
219 patients undergoing surgery in spinal block. Each curve
represents the cumulative percentage of patients remaining
event free. There is no difference in event-free survival in pa-
tients with bisoprolol compared with patients with placebo
(77.3% vs. 78.0%, Mantel-Cox log rank rest; P  0.90). Ninety-
five percent confidence intervals are shown at 3, 6, 9, and 12
months.
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genotyping success rate 98.4%). Measured allele frequen-
cies corresponded to frequencies observed in a Caucasian
population. All study subjects had a Caucasian genetic
background with Central European roots. The study pop-
ulation was in Hardy-Weinberg equilibrium for the adren-
ergic receptor polymorphisms rs1801252 (P  0.29),
rs1042713 (P  0.45), and rs1042714 (P  0.31) but not
for rs1801253 (P  0.0001; fig. S2, available on the ANES-
THESIOLOGY Web site at http://www.anesthesiology.org). In
the bisoprolol and placebo groups, approximately 60% of
the patients had the wild-type genotype of the ADRB1
Arg389Gly polymorphism (Arg389Arg), whereas approxi-
mately 40% of the patients had the variant genotype with at
least one mutated allele (Arg389Gly or Gly389Gly). Forty-
five of the genotyped patients had a positive primary out-
come compared with four primary outcomes occurring in
nongenotyped patients (45 of 186 vs. 4 of 33; P  0.20).
Twenty-one of the primary outcomes (21 of 112 [18.7%])
occurred in patients with wild-type genotype, and 24 (24 of
74 [32.4%]) occurred in patients with the variant genotype.
Figure 2 shows the Kaplan-Meier estimates of the primary
outcome measure in the two genotypes (log rank test, P
0.034). The variant genotype was associated with a signif-
icantly higher number of adverse events (hazard ratio, 1.87;
95% CI, 1.04–3.35; P  0.04). No differences in primary
outcome were observed after placebo or bisoprolol treat-
ment within the wild-type group or the variant group
(wild-type placebo 13 of 57 [22.8%] vs.wild-type bisoprolol
8 of 55 [14.5%], P 0.33; variant placebo 10 of 37 [27.0%]
vs. variant bisoprolol 14 of 37 [37.8%], P  0.45). No
association of primary outcome with any of the other ge-
notypes was observed (table 4).
Short-term Outcome Measures and Safety
Several biochemical markers of cardiovascular outcome,
including N-terminal brain natriuretic peptide, cardiac tro-
ponin T, pregnancy-associated plasma protein A, and cys-
tatin C, were determined in all patients to detect possible
minor perioperative damage or long-term effects that might
have escaped from clinical indicators and examinations.
Except for perioperative N-terminal brain natriuretic pep-
tide serum levels, for which moderate increases were pre-
viously reported after -blocker therapy,28 no differences
between groups were noted (fig. S3, available on the ANES-
THESIOLOGY Web site at http://www.anesthesiology.org).
Twenty-four–hour Holter electrocardiogram detected peri-
operative ischemic events in 8 patients (6 placebo and 2
bisoprolol patients; P  0.13). Six of the seven genotyped
patients with Holter-detected cardiac ischemia were Gly
carriers in the ADRB1 Arg389Gly polymorphism (6 of 7 vs.
1 of 7; P 0.03). The administration of bisoprolol doubled
the number of patients experiencing bradycardia (bisopro-
lol 47 of 110 [43%] vs. placebo 23 of 109 [21%]; P 0.02)
(figs. S4–S7, available on the ANESTHESIOLOGY Web site at
http://www.anesthesiology.org). Multivariate logistic re-
gression identified bisoprolol and the level of sympathicus
block as important predictors of bradycardia (table 5).
Blood pressure was significantly decreased in bisoprolol
patients (fig. S7, available on the ANESTHESIOLOGY Web site at
http://www.anesthesiology.org), but the number of hypo-
tensive episodes did not reach statistical significance (biso-
prolol 61 of 110 [55%] vs. placebo 49 of 109 [45%]; P 
0.12). Predictors of hypotension were the concomitant use
of spinal clonidine, bradycardia itself, and the ADRB2 poly-
morphism Gly16Arg (table 6). Baseline heart rate or peri-
Table 4. Cox Proportional Hazard Models for Primary
Outcome
Hazard Ratio
(95% CI) P Value
Univariate models
Group 0.97 (0.55–1.69) 0.90
Age 0.99 (0.97–1.03) 0.97
Sex 0.98 (0.56–1.71) 0.93
1 Ser49Gly-variant 1.57 (0.82–2.98) 0.17
1 Arg389Gly-variant 1.87 (1.04–3.35) 0.04
2 Gly16Arg-variant 0.62 (0.35–1.11) 0.11
2 Gln27Glu-variant 1.40 (0.73–2.66) 0.31
Bradycardia 1.22 (0.65–2.26) 0.54
Hypotension 1.51 (0.85–2.66) 0.16
Lee score 1.11 (0.82–1.52) 0.50
Use of statins 0.67 (0.36–1.22) 0.19
History of smoking (pack-years) 1.01 (0.99–1.02) 0.12
NT-proBNP perioperative fold-change 0.61 (0.29–1.29) 0.20
Multivariate model
1 Arg389Gly-variant 1.87 (1.04–3.35) 0.04
NT-proBNP  N-terminal pro brain natriuretic peptide. Fig. 2. Kaplan-Meier plot for adverse cardiac events during 1 yr
of follow-up stratified to the wild type (WT) or the variant
(heterozygous and mutant) of the 1-adrenergic receptor poly-
morphism Arg389Gly. Each curve represents the cumulative
percentage of patients remaining event free. There is a signifi-
cant difference in event-free survival in patients with the wild-
type genotype compared with patients with the variant (81.3%
vs. 67.6%, Mantel-Cox log rank test; P  0.034). Ninety-five
percent confidence intervals are shown at 3, 6, 9, and 12
months.
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operative changes in heart rate were not predicted by any
of the determined adrenergic receptor polymorphisms.
The average administered dose of bisoprolol per day of
treatment did not differ between Arg389Arg genotype and
Gly carriers (6.3  2.4 vs. 6.7  2.0 mg; P  0.42). Sixty
percent of the patients had a history of smoking, and
approximately 16% had chronic obstructive pulmonary dis-
ease. In each group, one patient experienced bronchos-
pasm necessitating medical therapy. There was a small but
significant postoperative decrease in peak expiratory flow
in the bisoprolol patients compared with placebo patients
(6  26% vs. 4  41%; P  0.046), which was not
predicted by any of the determined adrenergic receptor
genotypes nor the presence of chronic obstructive pulmo-
nary disease (for detailed lung function analysis, see figs.
S8–S10, available on the ANESTHESIOLOGY Web site at http://
www.anesthesiology.org).
Study Drug Administration and Compliance
Before administration of the first dose of study drug,
heart rate and blood pressure did not differ between the
two groups (table 1). Study drug was administered in all
patients before surgery (table 7). The mean duration of
drug administration was 4.9 days in the bisoprolol group
and 5.1 days in the placebo group. Because of low heart
rate and/or blood pressure, several patients received less
study drug. During the treatment period, heart rate was
on an average 10 beats/min lower in the bisoprolol
group compared with the placebo group (figs. S4–S6,
available on the ANESTHESIOLOGY Web site at http://www.
anesthesiology.org). In two patients of the bisoprolol
group, study drug was discontinued earlier because
-blocker therapy was indicated. Study drug was discon-
tinued earlier in three placebo patients and one bisopro-
lol patient because of adverse events (table 8).
Discussion
The results of this trial demonstrate that bisoprolol as
perioperative adjunct to spinal block has no benefit on
cardiovascular long-term outcome in patients with or at
risk of coronary artery disease undergoing noncardiac
surgery. The event-free survival in bisoprolol- and place-
bo-treated patients was identical after 1 yr of follow-up.
The clinical outcome was corroborated by serial deter-
minations of several sensitive prognostic biomarkers of
cardiovascular outcome.29
In this study, exclusively patients who met the criteria
by Mangano et al.4 were enrolled. More than one third of
these patients had overt cardiovascular disease. Despite
this disease burden, the immediate perioperative com-
plications were low, and no cardiovascular long-term
benefits were observed during 1-yr follow-up after peri-
operative bisoprolol therapy. The following explana-
tions for the lack of benefit can be offered. First, our
study cannot exclude a smaller benefit after bisoprolol
treatment than previously observed4 because of its rela-
tively small sample size. However, the largest difference
that our study could have been expected to find with
80% power was 15%, making the current trial reasonably
sensitive. Second, patients undergoing surgery with spi-
nal block may have a lower risk per se because of the
limited invasiveness of surgery conducted with neuraxial
blockade3 as well as its putative cardioprotective proper-
ties.14,30 In fact, nearly all patients underwent orthopedic
and urologic procedures with only intermediate surgical
risk as classified by the American Heart Association.2 This
idea is further supported by the low incidence of cardiac
ischemic events and the fact that pregnancy-associated
plasma protein A, a marker of atherosclerotic plaque insta-
bility, did not change perioperatively, as opposed to car-
diac surgery.22 Hence, our findings are in line with the
conclusions of a large retrospective cohort study31 and of a
Table 5. Predictors of Bradycardia
Odds Ratio
(95% CI) P Value
Univariate models
Group 2.95 (1.62–5.38) 0.0004
ASA physical status 0.36 (0.15–0.85) 0.02
Level of sympathicus block ( T4) 1.80(1.00–3.27) 0.05
Clonidine 1.34 (0.71–2.55) 0.37
Bupivacaine 1.03 (0.95–1.13) 0.48
1 Ser49Gly-WT 0.97 (0.47–2.01) 0.93
1 Arg389Gly-WT 1.62 (0.85–3.07) 0.14
2 Gly16Arg-WT 0.82 (0.43–1.54) 0.53
2 Gln27Glu-WT 0.67 (0.35–1.30) 0.24
BMI 1.04 (0.96–1.08) 0.64
Age 1.01 (0.98–1.04) 0.58
Multivariate model
Group 3.22 (1.74–5.98) 0.0002
Level of sympathicus block ( T4) 2.10 (1.12–3.92) 0.02
ASA  American Society of Anesthesiologists; BMI  body mass index; WT
 wild type.
Table 6. Predictors of Hypotension
Odds Ratio
(95% CI) P Value
Univariate models
Group 1.52 (0.90–2.60) 0.12
ASA physical status 1.18 (0.60–2.30) 0.63
Level of sympathicus block ( T4) 1.93 (1.09–3.43) 0.03
Bradycardia 2.45 (1.36–4.43) 0.003
Clonidine 9.42 (4.18–21.2) 0.0001
Bupivacaine 1.07 (0.99–1.16) 0.09
1 Ser49Gly-WT 0.42 (0.20–0.86) 0.02
1 Arg389Gly-WT 1.69 (0.93–3.05) 0.08
2 Gly16Arg-WT 2.05 (1.12–3.75) 0.02
2 Gln27Glu-WT 0.74 (0.41–1.36) 0.33
BMI 1.02 (0.96–1.07) 0.58
Age 1.00 (0.97–1.03) 0.94
Multivariate model
Bradycardia 2.99 (1.47–6.09) 0.003
Clonidine 11.0 (4.26–28.5) 0.0001
2 Gly16Arg-WT 2.28 (1.15–4.53) 0.02
ASA  American Society of Anesthesiologists; BMI  body mass index; WT
 wild type.
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recent meta-analysis32 dissuading from an unselective peri-
operative -blocker use in intermediate-risk conditions. A
recent guideline update on perioperative -blocker thera-
py3 restricts class I recommendations (“should be given”)
of perioperative -blocker therapy to patients receiving 
blockers for medical reasons and to patients undergoing
vascular surgery at high cardiac risk owing to the finding of
ischemia on preoperative testing. For patients with inter-
mediate surgical risk and less prominent medical predictors
of perioperative cardiovascular risk, as enrolled in our
study, a recommendation class IIa (“are probably recom-
mended”) or IIb (“may be considered”) can be made for
perioperative -blocker therapy with evidence level B (sin-
gle randomized trial or nonrandomized studies) or C (con-
sensus opinion of experts, case studies, or standard of
care), respectively. Therefore, the findings of this trial cer-
tainly add valuable new information in this context.
We found that genetic variations in the ADRB1 at
position 389 determined postoperative long-term event-
free survival. To date, no perioperative -blocker trial
has addressed the role of adrenergic receptor polymor-
phisms on outcome or treatment effect. We here show
that genetic variations in the ADRB1 at position 389
determined cardiovascular long-term outcome. In vitro
studies of isoproterenol stimulation showed that
Arg389Arg homozygous receptors produce higher levels
of cAMP because of enhanced G-protein coupling com-
pared with Arg389Gly and Gly389Gly receptors (“gain-
of-function” polymorphism).33,34 This is consistent with
clinical studies showing increased prevalence of hyper-
tension35 and myocardial infarction in Arg389Arg ho-
mozygotes.36 However, once ischemic heart disease is
established, individuals carrying the Arg389Arg homozy-
gous receptor may have a better prognosis. Using a
transgenic mouse model with cardiac-specific overex-
pression of either human Gly389Gly or Arg389Arg
ADRB1, Akhter et al. 37 showed that the Arg389Arg is
linked to improved protection against myocardial isch-
emia/reperfusion due to adaptive signaling mechanisms.
In addition, Arg389 homozygotes are more likely to
benefit from -blocker therapy.17,38 In the -Blocker
Evaluation of Survival Trial (BEST) heart failure study,
Arg389 homozygotes treated with bucindolol had the
largest benefit in mortality reduction (38%), whereas
Gly389 carriers (i.e., heterozygotes and Gly homozy-
gotes) had virtually no clinical benefit from bucindolol
therapy compared with placebo.20,39 Taken together,
these studies demonstrate a prominent biologic differ-
ence between wild-type ADRB1 Arg389Arg and Gly car-
riers (heterozygous Arg389Gly and homozygous
Gly389Gly) and justify the use of a dominant genetic
model in our analysis.
Our study sheds new light on past and future outcome
trials investigating the effectiveness of perioperative 
blockade. With respect to the study by Poldermans et
al.,5 it could be argued that enrollment of patients with
a positive dobutamine stress echocardiography might
introduce a bias toward the Arg389Arg ADRB1 geno-
type, because these patients exhibit enhanced respon-
siveness to catecholamines precipitating cardiac isch-
emia.40 Skilled echocardiography investigators were
reported to reliably predict a subject being homozygous
for the Arg389 allele or homozygous or heterozygous for
the Gly389 genotype.41 Therefore, these preselected pa-
tients would profit greatly from perioperative  block-
ade20,38 and explain the unusually high or “overesti-
mated” protection observed in this study. Likewise, the
benefits observed in the study by Mangano et al.4 might
have resulted from an uneven distribution of ADRB1
genotypes within strata. Even few patients could have
biased the outcome, as evidenced by the loss of statisti-
cal significance in this study, if in-hospital events were
included in the analysis. Finally, with respect to future
-blocker trials, our results imply that even large-scale
Table 7. Daily Dose of Bisoprolol and Placebo
Preop Postop POD 1 POD 2 POD 3 POD 4 POD 5 POD 6 POD 7 POD 8 POD 9 POD 10
B P B P B P B P B P B P B P B P B P B P B P B P
Total number of patients 110 109 110 109 110 107 97 93 76 78 63 65 56 58 44 47 36 41 28 33 17 25 12 17
Full dose* 89 85 18 53 45 75 39 65 40 62 31 60 30 53 26 41 21 33 19 27 9 21 9 16
Half dose† 21 24 36 31 49 22 45 20 27 12 27 4 21 4 16 5 12 7 7 6 7 4 3 1
Not treated‡ 0 0 54 25 16 10 13 8 9 4 5 1 5 1 2 1 3 1 2 0 1 0 0 0
Data are number of patients.
* Full dose  10 mg. † Half dose  5 mg. ‡ Not treated: because of heart rate less than 50 beats/min or systolic blood pressure less than 100 mmHg.
B  bisoprolol; P  placebo; POD  postoperative day; Postop  within 6 h after end of surgery; Preop  preoperative.
Table 8. Reported Serious Adverse Events
Bisoprolol
(n  110)
Placebo
(n  109)
Cardiovascular
Stroke 2 0
Bradycardia 0 3*
Hypotension 0 3*
Other
Bronchospasm 1 1
Psychosis/delirium 4 1
All 7 8
* Three patients having two reported serious adverse events.
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trials might be unable to ultimately decide whether peri-
operative  blockade is beneficial, unless detailed pharma-
cogenomic characterization of the study population will be
performed. In support of this idea is the recent experience
from the BEST study with more than 1,000 patients en-
rolled.39 Bucindolol therapy was only advantageous in the
Arg389Arg ADRB1 genotype and related to the degree of
antagonized adrenergic activity and not—as previously
speculated—by protection against excessive sympatholy-
sis.20 The question of whether  blockers reduce cardiac
complications in patients selected by medical comorbidi-
ties is currently being addressed by the PeriOperative ISch-
emic Evaluation (POISE) trial.42 However, to generate con-
vincing conclusions on the efficiency of perioperative 
blockade, the investigators of this trial will need to deter-
mine relevant, i.e., disease-modifying, genotypes in their
study population.
The results of our study also show an increased inci-
dence of bradycardia and hypotension in the bisoprolol
group, whereas bronchospasm only occurred in one
bisoprolol and one placebo patient. Hypotension was
particularly occurring if spinal clonidine was added to
prolong the duration of the block. In a retrospective
analysis, -blocker use was recently shown to increase
all-cause mortality in patients with a Revised Cardiac
Risk Index of 0–1.31 Although we were unable to show
an association of hemodynamic sequelae with long-term
outcome and some small studies reported good toler-
ance of neuraxial blockade with  blockers,5,6 the lack
of clear benefit in our patients highlights the need to
carefully balance the risk and benefits of preventive
perioperative  blockade, specifically in patients under-
going surgery with sympatholytic spinal block. Interest-
ingly, the presence of the ADRB2 Gly16Gly genotype
doubled the risk of hypotension. This finding is in con-
trast to a recent study evaluating the role of ADRB2
polymorphisms in young pregnant women,43 a condi-
tion that is clearly different from the elderly patients
with cardiovascular disease and multidrug therapy in our
study. Also, the literature on this polymorphism is not
conclusive because systemic infusion of isoproterenol
evokes greater vasodilation in Arg16 than Gly16 homozy-
gotes,44 whereas local infusion demonstrates a greater
vasodilator response in Gly16 than Arg16 homozy-
gotes.45 Moreover, there is strong linkage disequilibrium
between codons 16 and 27 of the ADRB2 polymorphism,
making the interpretation of clinical data difficult. Al-
though polymorphisms of the ADRB2 were previously
reported to be of relevance in asthma and chronic ob-
structive pulmonary disease patients,46 we were unable
to associate baseline or perioperative changes in pulmo-
nary function to any of the investigated polymorphisms.
Recent placebo-controlled studies evaluating the pro-
tection of perioperative  blockade used metoprolol as
study drug.9–11 However, metoprolol is subject to exten-
sive stereoselective metabolism. Polymorphic metabo-
lism of  blockers is of clinical importance because poor
metabolizers with genetic variants of cytochrome P450
may have increased plasma levels, whereas fast metabo-
lizers may have insufficient  blockade.47 Stereoselective
metabolism related to genetic background was also re-
ported for carvedilol.48 Therefore, we have chosen biso-
prolol as primary study drug because it is independent of
clinically relevant genetic heterogeneity of drug metab-
olism.49
Study Limitations
Although all efforts were undertaken to maintain effi-
cient blinding for the study drug throughout the trial, we
cannot completely rule out that titration of the study
drug to heart rate and blood pressure may have affected
blinding. Another limitation of this study is that only
84.9% of the study patients were genotyped for the
Arg389Gly polymorphism, which may have biased our
findings. However, primary outcome events were evenly
distributed between genotyped and nongenotyped indi-
viduals, and only 4 of the 49 events occurred in the
nongenotyped patients.
We found a significant departure from Hardy-Weinberg
equilibrium for ADRB1 Arg389Gly polymorphism with
an excess of homozygous mutants (Gly389Gly). To ex-
clude genotyping errors, we have carefully regenotyped
patients, and the data were interpreted by three inde-
pendent individuals. A likely reason for the observed
deviation from Hardy-Weinberg equilibrium may be the
obvious selection bias introduced in our study popula-
tion because of inclusion and exclusion criteria of this
randomized controlled trial. In fact, patients with a pre-
defined cardiovascular risk and/or disease profile were
enrolled. Also, mortality bias (differential survival of
marker carriers) due to varying genetic and environmen-
tal background may have occurred. This is of particular
relevance in our elderly study population at the end of
life expectancy. Finally, we cannot rule out that the
observed excess of homozygous Gly carriers might have
contributed to genotype-related difference in outcome
in our study population. Together, our data should be
confirmed in a prospective clinical trial specifically de-
signed and adequately powered to detect genotype-spe-
cific differences in cardiovascular outcome in patients
with or at risk of coronary artery disease.
Conclusions
The results of this study provide evidence that wide-
spread -blocker prophylaxis for patients with or at risk
of coronary artery disease having surgery with spinal
block is not indicated. The results of our study also
suggest that genetic heterogeneity of ADRB1 may trans-
late into differences in clinical outcome, and further
imply that future trials on perioperative -blocker ther-
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apy should genotype the study population to properly
interpret study results. Although we were unable to
differentiate specific responses of adrenergic receptor
genotypes to bisoprolol therapy, an increasing body of
evidence suggests that patients with defined adrenergic
receptor genotypes may profit from  blockade,
whereas others do not. Therefore, adrenergic receptor
genotyping could help to optimize drug therapy by max-
imizing efficacy and limiting toxicity.
The authors thank their colleagues (Nadia Dettori, M.D., Ines von Rothen,
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